Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Peripheral Blood Gene Expression Transcriptional Profiling Predicts Disease Progression in Primary Progressive Multiple Sclerosis
Multiple Sclerosis
ES1 - Emerging Science 1 (12:09 PM-12:15 PM)

Accurate prediction of long-term disease outcome remains a challenge for patients with primary progressive multiple sclerosis (PPMS).

To develop blood transcriptome-based prognostic model to predict severe disease progression in untreated PPMS patients. 

Peripheral blood samples of PPMS patients included in the placebo-arm of the ORATORIO clinical trial (NCT01194570), were subjected to RNA-sequence analysis by Illumina NovaSeq S2. We applied 2-levels cross-validation algorithm (www.partek.com) to predict 12-weeks confirmed disability progression (12W CDP) during 120 weeks follow up, and the percent of brain volume change (PBVC) at 24, 48 and 120 weeks of follow-up.

RNA samples from 65 PPMS patients, age 43.9±1.4 years, female/male ratio 21/44, baseline EDSS 4.5±0.2 were analyzed. Correct classification rate of the 37% of patients with 12W CDP was 90.8% (95% CI 80.6 – 100.0%) using a 10-gene classifier. Correct classification rates of 63%, 57% and 64% of patients with 24, 48 and 120 weeks of brain volume change respectively, was 74.0%, (95% CI 65.1% – 83.0%), 84.0%, (95% CI 75.1%-93.1%) and 82.9% (95% CI 73.8%-95.6%), respectively.

Transcriptome data correctly predicts disability progression and brain volume change in untreated PPMS patients that could benefit from early treatment.

Michael Gurevich, MD (Sheba Medical Center)
Dr. Gurevich has nothing to disclose.
Rina I. Falb, PhD (Medison Pharma) Dr. Falb has nothing to disclose.
No disclosure on file
No disclosure on file
Shay Menascu, MD (Pediatric Neurology Unit, Dana Pediatric Hospital,) No disclosure on file
Mark Dolev Mark Dolev has nothing to disclose.
Anat Achiron, MD, PhD, FAAN (Sheba Medical Center, Tel-Hashomer) Dr. Achiron has nothing to disclose.